vitamin B9 folate liposomal
Selected indexed studies
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. (Eur J Cancer, 2019) [PMID:30654298]
- Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs. (Cancer Sci, 2022) [PMID:35445479]
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. (Lancet, 2016) [PMID:26615328]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs. (2022) pubmed
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. (2019) pubmed
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. (2016) pubmed
- Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial. (2023) pubmed
- Folate receptors. (1996) pubmed
- Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial. (2024) pubmed
- Ultrasound-Responsive Nanocarriers Delivering siRNA and Fe(3)O(4) Nanoparticles Reprogram Macrophages and Inhibit M2 Polarization for Enhanced NSCLC Immunotherapy. (2024) pubmed
- Preparation and effects of functionalized liposomes targeting breast cancer tumors using chemotherapy, phototherapy, and immunotherapy. (2024) pubmed
- Enzymes as drugs. (1977) pubmed
- Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma. (2025) pubmed